Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Hematopoietic Mononuclear Cell Transplant with Minimal Gvhd in up to Completely Mismatched Unrelated Recipients

Suzanne T Ildstad, MD

Blood (2019) 134 (Supplement_1): 3243.

https://doi.org/10.1182/blood-2019-130943

Published: 2019

Journal Articles

Diagnostic and Prognostic Role of Fecal Calprotectin As a Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature

Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Ali Younas Khan, MD, Anum Qureshi, Muhammad Abu Zar, MD, Ceren Durer, MD, Seren Durer, MD, Ahmad Kamal, MD, Insija Ilyas Selene, MBBS, Jemin Aby Jose, MD, Muhammad Jahanzeb Khalil, MD, Hafiz Muhammad Fazeel, MD, Muhammad Usman, MD, Awais Ijaz, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5725.

https://doi.org/10.1182/blood-2018-99-109857

Published: 2018

Journal Articles

First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning

Wolfgang Bethge, MD, Stephan Mielke, MD, Dietger Niederwieser, MD, Roland Meisel, MD, Donald w. Bunjes, MD, Arne Brecht, MD, Jurgen Kuball, MD, Sandra Karitzky, PhD, Silke Holtkamp, Christiane Siewert, PhD, Stefanie Pflitsch, Michael Schumm, DVM, Matthias K. Eyrich, MD, Vladan Vucinic, Markus Wiesneth, MD, Kasper Westinga, Rupert Handgretinger, MD PhD

Blood (2017) 130 (Supplement 1): 213.

https://doi.org/10.1182/blood.V130.Suppl_1.213.213

Published: 2017

Journal Articles

Blinatumomab + Tyrosine Kinase Inhibitors with No Chemotherapy in BCR-ABL-Positive or IKZF1-Deleted or FLT3-ITD-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia Patients: High Molecular Remission Rate and Toxicity Profile

Andrey N. Sokolov, MD, Elena N. Parovichnikova, MD PhD, Vera V. Troitskaya, MD PhD, Larisa A. Kuzmina, MD PhD, Irina V. Galtseva, Sergei M. Kulikov, PhD, Sergey N. Bondarenko, PhDMD, Julia O. Davidova, Nikolay M. Kapranov, Irina A. Lukyanova, MD, Tatiana I. Lobanova, MD, Ekaterina I. Usikova, MD, Ksenija I. Zarubina, MD, Valeriy G. Savchenko

Blood (2017) 130 (Supplement 1): 3884.

https://doi.org/10.1182/blood.V130.Suppl_1.3884.3884

Published: 2017

Journal Articles

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Blood (2017) 130 (Supplement 1): 4484.

https://doi.org/10.1182/blood.V130.Suppl_1.4484.4484

Published: 2017

Journal Articles

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

Susan Prockop, MD, Ekaterina Doubrovina, MD PhD, Irene Rodriguez-Sanchez, Aisha N. Hasan, MD, Juliet Barker, MBBS, H.R. Castro-Malaspina, MD, Parastoo B. Dahi, MD, Sergio A. Giralt, MD, Boglarka Gyurkocza, MD, Nancy A. Kernan, MD, Guenther Koehne, MDPhD, Esperanza B. Papadopoulos, MD, Doris Ponce, MD, Craig S. Sauter, MD, Virginia Escobedo, RN, Victoria Szenes, PNP, Karim Baroudy, BS, Alison Slocum, MA, Richard J. O'Reilly, MD

Blood (2017) 130 (Supplement 1): 747.

https://doi.org/10.1182/blood.V130.Suppl_1.747.747

Published: 2017

Journal Articles

Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Benjamin L. Lampson, MD PhD, Haesook T Kim, PhD, Matthew S. Davids, MD, Jeremy S. Abramson, MD MMSc, Arnold S. Freedman, MD, Caron A. Jacobson, MD, Philippe Armand, MD PhD, Robin M. Joyce, MD, Jon E. Arnason, MD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, Samantha Huang, Joshua Fein, John Hanna, Stacey Marie Fernandes, BS, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 1734.

https://doi.org/10.1182/blood.V130.Suppl_1.1734.1734

Published: 2017

Journal Articles

Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease

Nicolaus Kröger, MD, Sharifah Shahnaz Syed Abd Kadir, MD, Tatjana Zabelina, MD, Christine Wolschke, MD, Francis A. Ayuk, MD, Anita Badbaran, Maximilian Christopeit, MD

Blood (2016) 128 (22): 2242.

https://doi.org/10.1182/blood.V128.22.2242.2242

Published: 2016

Journal Articles

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Ifigeneia Tzannou, MD, Anastasia Papadopoulou, PhD, Ayumi Watanabe, Manik Kuvalekar, Adrian P. Gee, PhD, Swati Naik, MD, Caridad Martinez, MD, Kathryn S. Leung, Ghadir S. Sasa, MD, Robert A. Krance, MD, George Carrum, MD, Carlos A. Ramos, MD, Bambi Grilley, Malcolm K. Brenner, MD PhD, Cliona M. Rooney, PhD, Helen E Heslop, MD DSc (Hon), Ann M. Leen, PhD, Bilal Omer, MD

Blood (2016) 128 (22): 501.

https://doi.org/10.1182/blood.V128.22.501.501

Published: 2016

Journal Articles

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Bilal Omer, MD, Anastasia Papadopoulou, PhD, Nikita Koottiyaniyil, Adrian P. Gee, PhD, Swati Naik, MD, Caridad Marinez, MD, Leung Kathryn, MD, Ghadir S. Sasa, MD, Robert A. Krance, MD, Bambi Grilley, RPh, Malcolm K. Brenner, MD PhD, Cliona M. Rooney, PhD, Helen E. Heslop, MD, Ann M. Leen, PhD, Ifigeneia Tzannou, MD

Blood (2015) 126 (23): 622.

https://doi.org/10.1182/blood.V126.23.622.622

Published: 2015

Journal Articles

Third-Party Donor Virus-Specific T Cells Are Efficacious in the Treatment of Refractory Viral Infection Following Allogeneic HSCT, but May Not Persist Post-Infusion

Barbara Withers, MBBS, Emily Blyth, MBBS, PhD, Leighton Clancy, PhD, Jane Burgess, Renee Simms, Kenneth Micklethwaite, MBBS, PhD, David Gottlieb, MBBS, MD

Blood (2015) 126 (23): 623.

https://doi.org/10.1182/blood.V126.23.623.623

Published: 2015

Journal Articles

Prolonged Lymphocytepenia after Bendamustine with or without Rituximab Treatment in Patients with Relapsed or Refractory Indolent B-Cell and Mantle Cell Lymphoma

Hideaki Saito, MD, Dai Maruyama, MD PhD, Akiko Miyagi Maeshima, MD PhD, Shin-ichi Makita, MD, Hideaki Kitahara, MD, Ken-ichi Miyamoto, MD, Suguru Fukuhara, MD, Wataru Munakata, MD, Tatsuya Suzuki, MD PhD, Yukio Kobayashi, Hirokazu Taniguchi, MD PhD, Kensei Tobinai

Blood (2014) 124 (21): 3066.

https://doi.org/10.1182/blood.V124.21.3066.3066

Published: 2014

Journal Articles

Therapeutic Infusion of Partially HLA-Matched Third-Party Virus-Specific T Cells in HSCT Patients with Refractory Viral Infection

Leighton Edward Clancy, PhD, Emily Blyth, Barbara Withers, Jane Burgess, Renee Simms, Chun Kei Kris Ma, B.Sc (MD MB BS FRACP FRCPA, Kenneth P. Micklethwaite, MD PhD, David Gottlieb, MB MDFRCPA FRACP

Blood (2014) 124 (21): 3835.

https://doi.org/10.1182/blood.V124.21.3835.3835

Published: 2014

Journal Articles

Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion

Brian C. Shaffer, MD, Andrew Flynn, David Moorshead, Zach Powell, Jennifer Hsu, RN, Rachel B Salit, MD, Frances T. Hakim, PhD, Ronald E. Gress, MD, Michael Bishop, MD, Juan Gea-Banacloche, MD, Steven Z. Pavletic, MD

Blood (2013) 122 (21): 4580.

https://doi.org/10.1182/blood.V122.21.4580.4580

Published: 2013

Journal Articles

Steroid Responsive T-Cell Mediated Pure Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation

Sandhya Kharbanda, M.D., James L. Zehnder, MD, Bertil Glader, M.D., Ph.D

Blood (2013) 122 (21): 5498.

https://doi.org/10.1182/blood.V122.21.5498.5498

Published: 2013

Journal Articles

Multicenter Study of “off-the-Shelf” Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT)

Ann M. Leen, PhD, Catherine M. Bollard, MD, Adam M. Mendizabal, MS, Elizabeth J. Shpall, MD, Paul Szabolcs, MD, Joseph H. Antin, MD, Neena Kapoor, MD, Sung-Yun Pai, MD, Scott D. Rowley, MD, Partow Kebriaei, M.D., Bambi J. Grilley, Adrian P. Gee, PhD, Malcolm K. Brenner, MD, PhD, Cliona M. Rooney, PhD, Helen E. Heslop, MD

Blood (2012) 120 (21): 457.

https://doi.org/10.1182/blood.V120.21.457.457

Published: 2012

Journal Articles

Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant

Ulrike Gerdemann, MD, Usha L Katari, Jacqueline Keirnan, John A. Craddock, M.D., Janet Salinas, Hao Liu, PhD, Caridad Martinez, MD, Alana Kennedy-Nasser, MD, Kathryn Leung, MD, Stephen Gottschalk, MD, Adrian P. Gee, PhD, Robert A. Krance, MD, Malcolm K. Brenner, MD, PhD, Cliona M. Rooney, PhD, Helen E. Heslop, MD, Ann M. Leen, PhD

Blood (2012) 120 (21): 223.

https://doi.org/10.1182/blood.V120.21.223.223

Published: 2012

Journal Articles

Identification of Characteristic Findings by Abdominal Magnetic Resonance Imaging in Acute Intestinal Graft Versus Host Disease

Stefan A. Klein, Johannes Budjan, Daniela Heidenreich, Ulrike Attenberger, Sebastian Kreil, Stefan Schönberg, Wolf-Karsten Hofmann, Henrik J. Michaely

Blood (2012) 120 (21): 4170.

https://doi.org/10.1182/blood.V120.21.4170.4170

Published: 2012

Journal Articles

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

Blood (2012) 120 (21): 2720.

https://doi.org/10.1182/blood.V120.21.2720.2720

Published: 2012

Journal Articles

Long-Term Follow-up of Patients with HIV-Related Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Phase II Study with Rituximab and CHOP (R-CHOP)

Josep-Maria Ribera, MD, PhD, Mireia Morgades, Albert Oriol, Eva González-Barca, MD, Pilar Miralles, Armando Lopez-Guillermo, Santiago Gardella, Andrés López, Eugènia Abella, Blanca Xicoy, MD, Marta Garcia, Evarist Feliu, MD, PhD

Blood (2011) 118 (21): 4980.

https://doi.org/10.1182/blood.V118.21.4980.4980

Published: 2011

NARROW

Hematopoietic Mononuclear Cell Transplant with Minimal Gvhd in up to Completely Mismatched Unrelated Recipients

Diagnostic and Prognostic Role of Fecal Calprotectin As a Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature

First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning

Blinatumomab + Tyrosine Kinase Inhibitors with No Chemotherapy in BCR-ABL-Positive or IKZF1-Deleted or FLT3-ITD-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia Patients: High Molecular Remission Rate and Toxicity Profile

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Third-Party Donor Virus-Specific T Cells Are Efficacious in the Treatment of Refractory Viral Infection Following Allogeneic HSCT, but May Not Persist Post-Infusion

Prolonged Lymphocytepenia after Bendamustine with or without Rituximab Treatment in Patients with Relapsed or Refractory Indolent B-Cell and Mantle Cell Lymphoma

Therapeutic Infusion of Partially HLA-Matched Third-Party Virus-Specific T Cells in HSCT Patients with Refractory Viral Infection

Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion

Steroid Responsive T-Cell Mediated Pure Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation

Multicenter Study of “off-the-Shelf” Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT)

Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant

Identification of Characteristic Findings by Abdominal Magnetic Resonance Imaging in Acute Intestinal Graft Versus Host Disease

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

Long-Term Follow-up of Patients with HIV-Related Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Phase II Study with Rituximab and CHOP (R-CHOP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only